Skip to main content
Venus Medtech (Hangzhou) Inc. logo

Venus Medtech (Hangzhou) Inc. — Investor Relations & Filings

Ticker · 2500 ISIN · CNE100003PJ8 HKEX Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2025-11-11 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2500

About Venus Medtech (Hangzhou) Inc.

http://www.venusmedtech.com

Venus Medtech (Hangzhou) Inc. is an innovation-driven medical device company specializing in the research, development, manufacturing, and commercialization of transcatheter solutions for structural heart diseases. The company focuses on bioprosthetic heart valves, establishing a comprehensive pipeline that addresses aortic, pulmonary, mitral, and tricuspid valve diseases. Its product portfolio includes transcatheter aortic valve replacement (TAVR) solutions, and it is committed to addressing unmet demand in TPVR and TMVR. The company also develops solutions for hypertension, such as renal artery denervation ablation, and related surgical accessory products. Its products are commercialized globally, reaching over 60 countries and regions across Asia, Europe, and the Americas.

Recent filings

Filing Released Lang Actions
MAJOR TRANSACTION IN RELATION TO DISPOSAL OF PROPERTY CLOSURE OF REGISTER OF MEMBERS AND CHANGE IN USE OF PROCEEDS FROM THE INITIAL GLOBAL OFFERING
Regulatory Filings Classification · 95% confidence The document is a formal announcement by Venus Medtech (Hangzhou) Inc. regarding a 'Major Transaction' involving the disposal of property and a change in the use of proceeds. It details the terms of a Disposal Agreement, listing rules implications, and the requirement for shareholder approval at an EGM. This fits the definition of a major corporate transaction announcement, which is categorized under M&A Activity (TAR) in the provided schema, as it involves the sale of significant assets (industrial park property) and is subject to regulatory disclosure requirements.
2025-11-11 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2025
Regulatory Filings Classification · 86% confidence The document is the HKEX ‘‘Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities (Form FF301)’’ for the month ended 31 October 2025. It is a periodic regulatory compliance filing to Hong Kong Exchanges and Clearing Limited detailing movements in share capital, issued and treasury shares, share options, and share repurchases. It does not constitute an earnings release, annual report, dividend notice, or other narrowly defined category but is required under listing rules. Therefore it falls into the fallback category of general regulatory filings (RNS).
2025-11-05 English
VOLUNTARY ANNOUNCEMENT COMPLETION OF FULL PATIENT ENROLLMENT FOR CONFIRMATORY CLINICAL STUDY OF CARDIOVALVE TTVR
Regulatory Filings Classification · 85% confidence The document is a voluntary announcement on the Stock Exchange of Hong Kong regarding the completion of patient enrollment for a clinical study. It does not present financial results, management changes, share issues, or voting results, nor is it a formal annual or interim report. It is a standalone corporate announcement of business/R&D progress. Therefore, it does not fit specialized categories like ER, IR, MANG, or CAP, and is best classified as a general regulatory filing (RNS).
2025-10-24 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2025
Share Issue/Capital Change Classification · 88% confidence The document is a Hong Kong Stock Exchange (HKEX) prescribed Form FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts under Chapter 19B” detailing movements in authorised share capital, issued shares, treasury shares, share options and repurchases. It is not an earnings release, AGM material, or a call transcript, but a routine regulatory filing about share capital structure and movements. This aligns with announcements of share issues and capital changes (Code SHA).
2025-10-08 English
2025 INTERIM REPORT
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled '2025 INTERIM REPORT' and contains comprehensive financial statements, including the 'Condensed Consolidated Statement of Profit or Loss', 'Condensed Consolidated Statement of Financial Position', and 'Management Discussion and Analysis'. It covers a period shorter than a full fiscal year (six months ended June 30, 2025). It meets all criteria for an Interim/Quarterly Report. H1 2025
2025-09-29 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 August 2025
Regulatory Filings Classification · 85% confidence The document is a standardized monthly return (Form FF301) filed with the Hong Kong Exchange detailing movements in authorized/registered share capital, issued shares, share options, repurchases, and related confirmations under HKEX Listing Rules Chapter 19B. It is not a shareholder meeting notice, earnings release, annual or interim report, dividend notice, board change announcement, nor a proxy statement. This form does not constitute an investor presentation or full financial report but is a regulatory filing listing security movements. Therefore it best fits the fallback category for miscellaneous regulatory filings (RNS).
2025-09-03 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.